OCT Clinical delivers end-to-end clinical logistics services and manages the clinical supply life cycle with high efficiency.
Clinical Trial Supplies and Logistics is one of the key components which can determine the cost and outcome of an entire trial and impact its processes significantly. Therefore, our Clinical Trial Supplies and Logistics team tirelessly works on navigating logistical challenges, maximizing efficiency and ensuring an on-site delivery of investigational supplies.
Our ultimate goal is to set up streamlined clinical trial supply processes. To achieve that, we employ resources to avoid overproduction, oversupply, and inventory expiration.
Kristian Bakonyi
Project Manager
The R&D stage takes up a major part of a drug value, and therefore it is of utmost importance to avoid delays in supplies delivery, inventory expiration or issues with packaging.
OCT Clinical’s ever-growing presence in a number of regions allows us to provide our sponsors with deep expertise in global supply matters, including customs procedures, and local import and export regulations.
We deliver full-range management of medical and pharmaceutical supplies through the International Conference on Harmonisation (ICH GCP)-certified contract warehouses.
Clinical Supply Services provided by OCT Clinical:
– Lifecycle management
– Global procurement and storage
– Secondary packaging and additional labeling
– Distribution
– Drug accountability and destruction
– Import of study medication and supplies
– Export of biosamples
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
